Cargando…
Nanomedicine targets iron metabolism for cancer therapy
Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolism...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898713/ https://www.ncbi.nlm.nih.gov/pubmed/34962017 http://dx.doi.org/10.1111/cas.15250 |
_version_ | 1784663718420807680 |
---|---|
author | Lin, Liangru Chen, Hanqing Zhao, Ruifang Zhu, Motao Nie, Guangjun |
author_facet | Lin, Liangru Chen, Hanqing Zhao, Ruifang Zhu, Motao Nie, Guangjun |
author_sort | Lin, Liangru |
collection | PubMed |
description | Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) Abs, and cytotoxic ligands conjugated to transferrin, has become a considerable strategy for cancer therapy. However, there remain major limitations for potential translation to the clinic based on the regulation of iron metabolism in cancer treatment. Nanotechnology has made great advances for cancer treatment by improving the therapeutic potential and lowering the side‐effects of the proved drugs and those under various stages of development. Early studies that combined nanotechnology with therapeutic means for the regulation of iron metabolism have shown certain promise for developing specific treatment options based on the intervention of cancer iron acquisition, transportation, and utilization. In this review, we summarize the current understanding of iron metabolism involved in cancer and review the recent advances in iron‐regulatory nanotherapeutics for improved cancer therapy. We also envision the future development of nanotherapeutics for improved treatment for certain types of cancers. |
format | Online Article Text |
id | pubmed-8898713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88987132022-03-11 Nanomedicine targets iron metabolism for cancer therapy Lin, Liangru Chen, Hanqing Zhao, Ruifang Zhu, Motao Nie, Guangjun Cancer Sci Review Articles Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) Abs, and cytotoxic ligands conjugated to transferrin, has become a considerable strategy for cancer therapy. However, there remain major limitations for potential translation to the clinic based on the regulation of iron metabolism in cancer treatment. Nanotechnology has made great advances for cancer treatment by improving the therapeutic potential and lowering the side‐effects of the proved drugs and those under various stages of development. Early studies that combined nanotechnology with therapeutic means for the regulation of iron metabolism have shown certain promise for developing specific treatment options based on the intervention of cancer iron acquisition, transportation, and utilization. In this review, we summarize the current understanding of iron metabolism involved in cancer and review the recent advances in iron‐regulatory nanotherapeutics for improved cancer therapy. We also envision the future development of nanotherapeutics for improved treatment for certain types of cancers. John Wiley and Sons Inc. 2022-02-07 2022-03 /pmc/articles/PMC8898713/ /pubmed/34962017 http://dx.doi.org/10.1111/cas.15250 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Articles Lin, Liangru Chen, Hanqing Zhao, Ruifang Zhu, Motao Nie, Guangjun Nanomedicine targets iron metabolism for cancer therapy |
title | Nanomedicine targets iron metabolism for cancer therapy |
title_full | Nanomedicine targets iron metabolism for cancer therapy |
title_fullStr | Nanomedicine targets iron metabolism for cancer therapy |
title_full_unstemmed | Nanomedicine targets iron metabolism for cancer therapy |
title_short | Nanomedicine targets iron metabolism for cancer therapy |
title_sort | nanomedicine targets iron metabolism for cancer therapy |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898713/ https://www.ncbi.nlm.nih.gov/pubmed/34962017 http://dx.doi.org/10.1111/cas.15250 |
work_keys_str_mv | AT linliangru nanomedicinetargetsironmetabolismforcancertherapy AT chenhanqing nanomedicinetargetsironmetabolismforcancertherapy AT zhaoruifang nanomedicinetargetsironmetabolismforcancertherapy AT zhumotao nanomedicinetargetsironmetabolismforcancertherapy AT nieguangjun nanomedicinetargetsironmetabolismforcancertherapy |